The Conversation (0)
Chart
Detailed Quote
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Featured Articles and Interviews
Press Releases
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.